Sanford C. Bernstein Cuts Medline (NASDAQ:MDLN) Price Target to $54.00

Key Points

• Sanford C. Bernstein cut its price target on Medline to $54 (from $56) while maintaining an "outperform" rating, implying roughly a 29.7% upside from the current share price.
• Medline beat Q1 expectations—reporting $7.35 billion in sales and $0.33 EPS (vs. $0.29 est.) and raising organic sales guidance—but profitability weakened (net income down ~25.8%, adjusted EBITDA down ~10.6% and gross margin compression), which spurred an intraday share decline and prompted some analyst target trims.

Medline (NASDAQ:MDLN - Get Free Report) had its price target dropped by equities researchers at Sanford C. Bernstein from $56.00 to $54.00 in a report issued on Thursday,Benzinga reports. The firm currently has an "outperform" rating on the stock. Sanford C. Bernstein's price target suggests a potential upside of 29.65% from the stock's current price.

MDLN has been the subject of a number of other reports. Leerink Partners set a $56.00 price target on shares of Medline in a report on Wednesday, February 25th. Weiss Ratings cut shares of Medline from a "hold (c)" rating to a "hold (c-)" rating in a report on Monday, April 27th. Stifel Nicolaus set a $55.00 price objective on Medline in a research report on Wednesday, February 25th. Deutsche Bank Aktiengesellschaft initiated coverage on Medline in a report on Monday, January 12th. They set a "hold" rating and a $40.00 target price for the company. Finally, BNP Paribas Exane began coverage on Medline in a research note on Monday, January 12th. They issued a "neutral" rating and a $38.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $50.81.

Medline Stock Performance

NASDAQ MDLN traded down $0.36 on Thursday, reaching $41.65. 492,568 shares of the stock traded hands, compared to its average volume of 5,402,719. Medline has a 12 month low of $34.89 and a 12 month high of $50.88. The stock's fifty day moving average price is $44.57.

Medline (NASDAQ:MDLN - Get Free Report) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.33 earnings per share for the quarter, beating the consensus estimate of $0.29 by $0.04. The firm had revenue of $7.35 billion during the quarter. The firm's revenue for the quarter was up 10.7% on a year-over-year basis. On average, research analysts predict that Medline will post 1.46 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Medline

Several hedge funds have recently bought and sold shares of the business. North Star Investment Management Corp. boosted its position in Medline by 60.2% during the 1st quarter. North Star Investment Management Corp. now owns 1,362 shares of the company's stock worth $61,000 after acquiring an additional 512 shares during the period. Sound Income Strategies LLC acquired a new position in shares of Medline in the 4th quarter valued at about $25,000. Entrust Financial LLC purchased a new stake in shares of Medline in the fourth quarter worth approximately $26,000. NBC Securities Inc. acquired a new stake in shares of Medline during the fourth quarter worth approximately $28,000. Finally, Whipplewood Advisors LLC acquired a new stake in shares of Medline during the first quarter worth approximately $30,000.

More Medline News

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Q1 beat on top and bottom lines — Medline reported ~ $7.4B in net sales (up 10.7% YoY) and beat EPS consensus ($0.33 vs $0.29), and raised full‑year organic sales guidance to 8.5%–9.5%, supporting longer‑term growth expectations. Medline Reports First Quarter 2026 Results
• Positive Sentiment: New product/tech initiative — Medline launched its AI‑powered Mpower platform to bolster supply‑chain resiliency, which investors may view as a differentiator for long‑term customer retention and margin improvement potential. Medline Launches AI‑Powered Mpower Platform
• Positive Sentiment: Analyst support — Multiple firms reiterated Buy/Outperform ratings and upbeat price targets (BTIG reaffirmed Buy with a $55 target; Piper Sandler reaffirmed Buy), supplying analyst backing that can limit downside and attract buyers. BTIG Reaffirms Buy Piper Sandler Reaffirms Buy
• Neutral Sentiment: Full earnings package posted — conference call transcript, slide deck and investor materials are available for deeper diligence; useful but not market‑moving by themselves. Medline Q1 Press Release / Slide Deck
• Negative Sentiment: Margins and profit declined — Net income fell ~25.8% to $239M and adjusted EBITDA dropped ~10.6%; gross margin compressed (from ~27.5% to ~25.0%) due to higher product costs (including tariff impacts) and growth‑related operating expenses, which has spooked investors about near‑term profitability. Q1 Earnings Call Transcript
• Negative Sentiment: Market reaction and commentary — The stock experienced a sharp intraday decline after the results as traders focused on margin pressure despite the sales beat; social and quant commentary flagged tariffs (~$85M impact) and IPO‑related costs as contributors to the profit drop. Medline slides as Q1 profit drops
• Negative Sentiment: Insider/institutional selling visible — Reports show substantial institutional and block sales by large holders since the IPO, which can weigh on supply/demand and investor sentiment (though there are some recent insider purchases). Quiver / Medonde Discussion on Insider Activity
• Negative Sentiment: Analyst trim on margin concerns — At least one shop trimmed its price target (Bank of America to $53) while keeping a Buy, highlighting that margin headwinds are tempering near‑term upside. TipRanks: BofA trims PT to $53

About Medline

Medline NASDAQ: MDLN is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.